Zelluna ASA and Strategic Share Management
In recent developments, Zelluna ASA has taken proactive steps to ensure an effective share management process surrounding its recent reverse share split. The Company, focusing on its mission to revolutionize cancer treatment with innovative therapies, has intricately communicated the key aspects of this decision to its stakeholders.
Understanding the Reverse Share Split
As noted in a recent announcement, Zelluna ASA is implementing a reverse share split with a ratio of 10:1. This strategic move is part of a broader effort to streamline capital and maintain a more favorable stock performance. The reverse split will consolidate shares, giving the Company an opportunity to enhance its market position.
Collaboration with Radforsk Investeringsstiftelse
To facilitate this share management, Zelluna ASA has collaborated with Radforsk Investeringsstiftelse. In a gesture of support for shareholders, Radforsk has agreed to provide shares without any compensation required. This initiative aims to ensure that all fractional shares resulting from the reverse split are rounded up, preventing any downward adjustment of shareholder equity.
Details of the Share Transfer
Recently, Radforsk transferred a total of 1730 shares to DNB Bank ASA, which acts as the registrar's department for Zelluna ASA. The transfer to DNB Bank was executed at a nominal price of NOK 1 per share, enabling the management of excess fractions efficiently during the share restructuring process. This thoughtful action demonstrates a strategic approach to maintaining shareholder interests.
Insight into Zelluna ASA's Mission
Zelluna ASA is dedicated to delivering groundbreaking treatments aimed at curing advanced solid cancers on a global scale. Their innovative approach works by integrating the most effective parts of the immune system, specifically utilizing pioneering 'off the shelf' T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). This unique therapy platform not only offers significant potential for diverse cancer detection but also sets out to expand access to life-saving treatments.
The Future for Zelluna ASA
The future looks promising for Zelluna ASA as it moves forward with its groundbreaking TCR-NK therapies. The currently leading program targets MAGE-A4, representing a pivotal step in providing innovative solutions for various solid cancers. With a robust pipeline of future therapies, the Company is well-positioned to continue its impactful work in biotechnology.
Leadership Commitment
Supported by a dynamic management team of experienced biotech entrepreneurs, Zelluna ASA is equipped to take its innovative therapies from discovery through to clinical development. Their vision encompasses delivering patient-centric and cost-effective treatments tailored to meet various health challenges related to advanced cancers.
Contact Information
For further inquiries regarding Zelluna ASA’s recent developments, interested parties may reach out to:
Hans Vassgård Eid, Chief Financial Officer, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632
Frequently Asked Questions
What is the reverse share split ratio for Zelluna ASA?
The reverse share split ratio for Zelluna ASA is set at 10:1.
How many shares did Radforsk transfer to DNB Bank ASA?
Radforsk transferred a total of 1730 shares to DNB Bank ASA.
What does Zelluna ASA aim to achieve with its therapies?
Zelluna ASA aims to provide transformative treatments that can cure advanced solid cancers safely and efficiently.
Who can provide more information about Zelluna ASA?
Hans Vassgård Eid, the CFO of Zelluna ASA, is available for further information.
What unique therapy platform does Zelluna ASA utilize?
Zelluna ASA utilizes T cell receptor (TCR) guided natural killer (NK) cell therapies in its innovative treatment approaches.
